Daily Anesthesiology Research Analysis
Analyzed 139 papers and selected 3 impactful papers.
Summary
Two high-quality randomized trials in obstetric anesthesia report clinically meaningful advances: adding esketamine to ropivacaine for epidural labor analgesia accelerated onset, reduced maternal side effects, and lowered postpartum depression risk; adding lidocaine to ropivacaine-sufentanil halved epidural-related maternal fever. A prospective perioperative study linked greater post-discharge opioid use to small but significant decrements in weekly EQ-5D quality-of-life values, informing future opioid-sparing strategies and economic endpoints.
Research Themes
- Obstetric anesthesia: opioid-sparing adjuvants and maternal outcomes
- Prevention of epidural-related maternal fever via local anesthetic modulation
- Perioperative opioid consumption and patient-reported quality of life
Selected Articles
1. Esketamine as an opioid-sparing adjuvant for epidural labour analgesia: a randomised, double-blind trial evaluating postpartum depression.
In a randomized double-blind trial of 200 nulliparous parturients, esketamine (0.3 mg/mL) added to ropivacaine 0.083% for epidural analgesia led to faster onset (5.9 vs 9.8 minutes), higher predominance of T8 sensory block, reduced ropivacaine consumption, markedly fewer maternal adverse events, and lower EPDS scores at 42 days versus sufentanil (0.3 µg/mL). The incidence of probable postpartum depression was significantly lower with esketamine.
Impact: This trial suggests an opioid-sparing epidural regimen that improves maternal safety and potentially reduces postpartum depression, a major public health burden. It integrates analgesic efficacy with mental health outcomes.
Clinical Implications: An esketamine-ropivacaine epidural mixture may replace opioid adjuvants to achieve faster onset, fewer side effects (pruritus, hypotension, urinary retention), and lower postpartum depression risk. Adoption should consider local protocols and monitoring, with further multicenter validation.
Key Findings
- Esketamine reduced onset time to analgesia (5.9 ± 0.6 vs 9.8 ± 1.7 minutes, P < 0.001).
- Higher predominance of T8 sensory block with esketamine (67.7% vs 45.9%, P < 0.001).
- Lower total ropivacaine consumption during the first stage of labor (−17%, P < 0.001).
- Marked reduction in maternal adverse events: pruritus 3.0% vs 45.9%, hypotension 4.0% vs 38.8%, urinary retention 3.0% vs 22.4% (all P < 0.001).
- Lower EPDS scores at 42 days and reduced probable PPD (4.0% vs 18.4%, P = 0.003).
Methodological Strengths
- Randomized, double-blind, controlled design with active comparator.
- Patient-centered outcomes including EPDS at 42 days postpartum.
Limitations
- Single-center trial with retrospective registry entry.
- No long-term neonatal outcomes or pharmacovigilance beyond 42 days.
Future Directions: Multicenter confirmatory RCTs, dose-finding for esketamine epidural concentrations, mechanistic studies on antidepressant effects, and long-term maternal-neonatal safety surveillance.
BACKGROUND: Opioid-based epidural analgesia, while effective, is frequently associated with maternal side effects such as pruritus and potential central sensitisation. Esketamine provides rapid analgesic and antidepressant effects at subanesthetic doses. We compared esketamine with sufentanil both added to 0.083% ropivacaine focusing on efficacy, maternal safety, and postpartum depression outcomes. METHODS: In this single-centre, randomised, double-blind, controlled trial, 200 nulliparous parturients (ASA I-II, 18-40 years, cervical dilatation 2-3 cm) requesting epidural analgesia
2. Addition of Lidocaine to Ropivacaine and Sufentanil for Epidural Labour Analgesia: A Randomised Double-Blind Study on the Incidence of Epidural-Related Maternal Fever.
In 400 laboring patients randomized to ropivacaine-sufentanil with or without lidocaine (0.5%), the lidocaine group had significantly lower ERMF incidence (14.1% vs 28.3%), an absolute risk reduction of 14.2%. Postoperative nausea, vomiting, and drowsiness were also reduced, without differences in glucose, mobilization, or length of stay.
Impact: This large double-blind RCT provides a simple modification to standard epidural mixtures that halves maternal fever, a frequent and consequential obstetric anesthesia complication.
Clinical Implications: Adding lidocaine to ropivacaine-sufentanil epidurals can substantially reduce ERMF without compromising recovery metrics. Obstetric anesthesia protocols may consider lidocaine as an anti-inflammatory adjunct, with attention to dosing and local practices.
Key Findings
- ERMF incidence was lower with lidocaine (14.1%) versus control (28.3%); absolute risk reduction 14.2%.
- Reductions in postoperative nausea, vomiting, and drowsiness in the lidocaine group.
- No significant differences in postoperative blood glucose, drain duration, time to mobilization, or length of stay.
Methodological Strengths
- Randomized, double-blind design with large sample size (n=400).
- Clinically relevant primary endpoint with clear definition (tympanic ≥38.0°C).
Limitations
- Single study setting with limited mechanistic biomarker assessment.
- Generalizability to different epidural mixtures and populations requires confirmation.
Future Directions: Replicate in diverse populations and settings; explore mechanistic pathways (e.g., cytokine profiling); assess neonatal outcomes and cost-effectiveness.
BACKGROUND: Epidural-related maternal fever (ERMF) is a common complication of labour analgesia. In vitro evidence suggests ropivacaine provokes inflammatory cytokine release, while lidocaine may exert anti-inflammatory effects. We hypothesized that the addition of lidocaine to a ropivacaine-based epidural solution would reduce the incidence of ERMF. METHODS: In this randomised, double-blind trial, 400 parturients received epidural analgesia with 0.075% ropivacaine and 0.5 μg/mL sufentanil, with or without 0.5% lidocaine. The primary outcome was the incidence
3. Opioid Intake and Quality of Life After Hospital Discharge From Major Surgery: A Health Economic Evaluation.
Among 606 opioid-naïve inpatients after major surgery, weekly post-discharge opioid dose was inversely associated with EQ-5D-5L utility values across three analytic approaches. Each 1-unit increase in the square root of MME corresponded to a 0.0108 decrease in EQ-5D-5L; predicted improvement with zero opioids averaged 0.0436 utility per week. Effects were small, suggesting that near-zero opioid use is required to exceed minimal important differences.
Impact: Provides quantitative, patient-level linkage between opioid consumption and quality-of-life decrements post-discharge, informing primary economic endpoints for analgesic trials and policy.
Clinical Implications: Supports opioid-sparing discharge protocols and sets realistic expectations: incremental reductions may yield small QOL gains; comprehensive multimodal analgesia targeting near-zero opioids may be needed to achieve clinically meaningful improvement.
Key Findings
- 606 patients contributed 2292 paired observations of EQ-5D-5L and MME.
- Within-person analysis: 1-unit increase in sqrt(MME) associated with −0.0108 EQ-5D-5L (SE 0.0011, P<.0001).
- Sensitivity analysis #1 (means by week, controlling for specialty): −0.0166 EQ-5D-5L per sqrt(MME) unit (P<.0001).
- Sensitivity analysis #2 (partial Kendall tau-b with Bonferroni correction) confirmed inverse association across weeks.
- Predicted improvement with zero opioids averaged 0.0436 EQ-5D-5L utility per week; effects small relative to minimal important difference.
Methodological Strengths
- Prospective longitudinal design with repeated within-person measures.
- Multiple sensitivity analyses using distinct statistical frameworks.
Limitations
- Observational design with potential residual confounding despite within-person comparisons.
- Effect sizes were small; smartphone-based surveys may introduce selection or response biases.
Future Directions: Use EQ-5D-5L as an a priori economic endpoint in randomized trials of analgesic strategies; test interventions that achieve near-zero opioid exposure; incorporate cost-utility analyses.
BACKGROUND: Earlier studies have not examined the extent to which reducing postoperative opioid use after patient discharge would improve the quality of life of opioid naïve patients, knowledge needed for economic evaluations of drugs and devices (applications) that reduce morphine milligram equivalents. We quantified associations between postoperative opioid use and patient-centered health outcomes using the EuroQol group's EQ-5D-5L values, recorded longitudinally. METHODS: Prospective observational data were collected for adult patients, without regular preoperativ